Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The...

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Low-density lipoprotein cholesterol (LDL-C) is a key modifiable risk factor for cardiovascular disease.
• European guidelines recommend LDL-C <55 mg/dL for very high-risk patients.
• The HEYMANS study investigated evolocumab's use in a German cohort.

Purpose of the Study:

• To describe clinical characteristics of patients initiating evolocumab.
• To assess LDL-C control in these patients.
• To evaluate evolocumab's effectiveness and safety in real-world practice.

Main Methods:

• Observational study of 380 patients in Germany.
• Data collected retrospectively (up to 6 months pre-initiation) and prospectively (up to 30 months post-initiation).
• Collected data included patient characteristics, lipid-lowering therapy (LLT), lipid values, and safety.

Main Results:

• Evolocumab initiation led to a median 53% LDL-C reduction within 3 months, sustained long-term.
• 59% of patients achieved the LDL-C goal (<55 mg/dL), with higher rates (69%) when combined with LLT.
• High persistence (90.6% at 1 year, 93.5% at 2.5 years) and a favorable safety profile (8% adverse drug reactions) were noted.

Conclusions:

• Evolocumab effectively and safely reduces LDL-C in clinical practice, corroborating prior findings.
• Rapid and sustained LDL-C lowering was observed, with high patient persistence.
• Combination therapy with evolocumab and LLT enhances achievement of LDL-C goals, underscoring the importance of intensive treatment strategies.